143 related articles for article (PubMed ID: 35372058)
1. A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer.
Huang SC; Lin CC; Teng HW; Lin HH; Chang SC; Lan YT; Wang HS; Yang SH; Chen WS; Jiang JK
Front Oncol; 2022; 12():808808. PubMed ID: 35372058
[TBL] [Abstract][Full Text] [Related]
2. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
[TBL] [Abstract][Full Text] [Related]
3. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
5. Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers.
Kodama H; Masuishi T; Wakabayashi M; Nakata A; Kumanishi R; Nakazawa T; Ogata T; Matsubara Y; Honda K; Narita Y; Taniguchi H; Kadowaki S; Ando M; Muro K
Clin Colorectal Cancer; 2023 Sep; 22(3):298-306. PubMed ID: 37270357
[TBL] [Abstract][Full Text] [Related]
6. First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials.
Vogel A; Kirstein MM
Innov Surg Sci; 2018 Jun; 3(2):85-86. PubMed ID: 31579770
[TBL] [Abstract][Full Text] [Related]
7. Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study.
Pericay C; Fernández Montes A; Alonso Orduña V; Macias Declara I; Asensio Martínez E; Rodríguez Salas N; Torres E; Cacho Lavín D; Rodríguez Alonso RM; Falcó E; Oliva JC; Cirera L
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760572
[TBL] [Abstract][Full Text] [Related]
8. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry.
Chen CC; Chang SC; Chang YY; Lin BW; Chen HH; Hsieh YY; Hsu HC; Hsieh MC; Ke TW; Kuan FC; Wu CC; Lu WC; Su YL; Liang YH; Chen JB; Huang HY; Tsai HL; Wang JY
Am J Cancer Res; 2023; 13(12):6333-6345. PubMed ID: 38187069
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type
Jiang W; Yu Q; Ning R; Zhao W; Wei C
Onco Targets Ther; 2018; 11():4271-4281. PubMed ID: 30100734
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.
You XH; Jiang YH; Fang Z; Sun F; Li Y; Wang W; Xia ZJ; Wang XZ; Ying HQ
ESMO Open; 2020 Mar; 4(Suppl 2):. PubMed ID: 32132090
[TBL] [Abstract][Full Text] [Related]
13. Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment.
Zheng P; Ren L; Feng Q; Zhu D; Chang W; He G; Ji M; Jian M; Lin Q; Yi T; Wei Y; Xu J
Am J Cancer Res; 2018; 8(11):2337-2345. PubMed ID: 30555748
[TBL] [Abstract][Full Text] [Related]
14. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
Salvatore L; Bensi M; Vivolo R; Zurlo IV; Dell'Aquila E; Grande R; Anghelone A; Emiliani A; Citarella F; Calegari MA; Ribelli M; Basso M; Pozzo C; Tortora G
Front Oncol; 2023; 13():1125013. PubMed ID: 36895480
[TBL] [Abstract][Full Text] [Related]
16. A study of gene variation in All-
Tao H; Shen M; Zhang X; Wang M; Wu Y; Sun H; Ling C; Yang Y; Chen K; Li D
J Gastrointest Oncol; 2022 Dec; 13(6):3009-3024. PubMed ID: 36636055
[TBL] [Abstract][Full Text] [Related]
17. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
18. Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with
Boyne DJ; Ngan E; Carbonell C; Wani RJ; Cirone Morris C; Martinez DJ; Cheung WY
Curr Oncol; 2023 Sep; 30(9):8220-8232. PubMed ID: 37754511
[TBL] [Abstract][Full Text] [Related]
19. Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.
Price T; Shen L; Ma B; Esser R; Chen W; Gibbs P; Lim R; Cheng AL
Asia Pac J Clin Oncol; 2019 Aug; 15(4):225-230. PubMed ID: 31090260
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital.
Yuan M; Wang Z; Zhao Y; Feng T; Lv W; Zhong H
Front Pharmacol; 2021; 12():632076. PubMed ID: 34122063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
